CN1089233C - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN1089233C
CN1089233C CN95195900A CN95195900A CN1089233C CN 1089233 C CN1089233 C CN 1089233C CN 95195900 A CN95195900 A CN 95195900A CN 95195900 A CN95195900 A CN 95195900A CN 1089233 C CN1089233 C CN 1089233C
Authority
CN
China
Prior art keywords
compound
alcohol
unsaturated fatty
compounds
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN95195900A
Other languages
English (en)
Chinese (zh)
Other versions
CN1162259A (zh
Inventor
M·杰克曼
朴学平
F·里希特
F·舒莫克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1089233(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1162259A publication Critical patent/CN1162259A/zh
Application granted granted Critical
Publication of CN1089233C publication Critical patent/CN1089233C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN95195900A 1994-10-26 1995-10-26 药物组合物 Expired - Lifetime CN1089233C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9421612.4 1994-10-26
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GB9422306.2 1994-11-04
GB9503553.1 1995-02-22
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021243700A Division CN100335063C (zh) 1994-10-26 1995-10-26 药物组合物

Publications (2)

Publication Number Publication Date
CN1162259A CN1162259A (zh) 1997-10-15
CN1089233C true CN1089233C (zh) 2002-08-21

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
CN95195900A Expired - Lifetime CN1089233C (zh) 1994-10-26 1995-10-26 药物组合物
CNB021243700A Expired - Lifetime CN100335063C (zh) 1994-10-26 1995-10-26 药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021243700A Expired - Lifetime CN100335063C (zh) 1994-10-26 1995-10-26 药物组合物

Country Status (25)

Country Link
US (1) US6352998B2 (OSRAM)
EP (2) EP0786986B1 (OSRAM)
JP (3) JP4155593B2 (OSRAM)
KR (1) KR100434682B1 (OSRAM)
CN (2) CN1089233C (OSRAM)
AT (2) ATE299017T1 (OSRAM)
AU (1) AU714254B2 (OSRAM)
BR (1) BR9509530A (OSRAM)
CA (1) CA2200966C (OSRAM)
CY (1) CY2211B1 (OSRAM)
CZ (1) CZ289773B6 (OSRAM)
DE (3) DE69525957T2 (OSRAM)
DK (2) DK1147766T3 (OSRAM)
ES (2) ES2173978T3 (OSRAM)
FI (2) FI119754B (OSRAM)
GB (1) GB2308546B (OSRAM)
HU (1) HU223840B1 (OSRAM)
MX (1) MX9702699A (OSRAM)
NO (2) NO316963B1 (OSRAM)
NZ (2) NZ295170A (OSRAM)
PL (1) PL184750B1 (OSRAM)
PT (2) PT1147766E (OSRAM)
SI (1) SI0786986T1 (OSRAM)
SK (1) SK284591B6 (OSRAM)
WO (1) WO1996013249A1 (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ267796A3 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
WO1999055332A1 (en) 1998-04-27 1999-11-04 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
IL156887A0 (en) * 2001-02-16 2004-02-08 Jomed Gmbh Implants with fk506
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AR035293A1 (es) * 2001-08-23 2004-05-05 Novartis Ag Composicion oftalmica.
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
WO2004071398A2 (en) * 2003-02-17 2004-08-26 Cipla Ltd Pharmaceutical patch
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0412581A (pt) * 2003-07-31 2006-09-19 Pharmacia & Upjohn Co Llc formulação dispersável de um agente antiinflamatório
JP5021456B2 (ja) * 2004-04-08 2012-09-05 ノバルティス アーゲー ヘキシレングリコール、所望によりオレイルアルコール、ジメチルイソソルバイドおよび／または中鎖トリグリセリドを含むピメクロリムス泡状組成物
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2948134B1 (en) * 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
CN109069418A (zh) * 2016-04-04 2018-12-21 药品配送方案有限公司 包含他克莫司的局部组合物
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474126A1 (en) * 1990-09-04 1992-03-11 Fujisawa Pharmaceutical Co., Ltd. Ointments containing tricyclic compound

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DK175235B1 (da) 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
EP0346427B1 (en) 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
EP0427680B1 (en) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
DE10199039I2 (de) 1993-10-22 2008-08-07 Hexal Ag Ind 25 Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474126A1 (en) * 1990-09-04 1992-03-11 Fujisawa Pharmaceutical Co., Ltd. Ointments containing tricyclic compound

Also Published As

Publication number Publication date
JP5599422B2 (ja) 2014-10-01
MX9702699A (es) 1997-06-28
CA2200966A1 (en) 1996-05-09
CN100335063C (zh) 2007-09-05
PL319599A1 (en) 1997-08-18
FI971018A0 (fi) 1997-03-11
SK52097A3 (en) 1997-09-10
GB9707484D0 (en) 1997-05-28
DK1147766T3 (da) 2005-08-29
PL184750B1 (pl) 2002-12-31
PT786986E (pt) 2002-07-31
BR9509530A (pt) 1997-10-14
AU3845195A (en) 1996-05-23
CN1401325A (zh) 2003-03-12
NZ331824A (en) 2000-01-28
GB2308546B (en) 1999-06-02
US20010031769A1 (en) 2001-10-18
NZ295170A (en) 1999-02-25
JP2012131827A (ja) 2012-07-12
AU714254B2 (en) 1999-12-23
CZ123297A3 (en) 1997-08-13
DE19581804T1 (de) 1998-01-22
HUT77140A (hu) 1998-03-02
JP2007145860A (ja) 2007-06-14
EP0786986B1 (en) 2002-03-20
ES2173978T3 (es) 2002-11-01
US6352998B2 (en) 2002-03-05
JP4155593B2 (ja) 2008-09-24
DE69534306D1 (de) 2005-08-11
EP0786986A1 (en) 1997-08-06
DK0786986T3 (da) 2002-04-29
ES2243369T3 (es) 2005-12-01
ATE214593T1 (de) 2002-04-15
CA2200966C (en) 2006-12-19
DE69525957D1 (de) 2002-04-25
EP1147766A3 (en) 2001-10-31
PT1147766E (pt) 2005-11-30
FI971018L (fi) 1997-04-18
SI0786986T1 (en) 2002-06-30
FI119755B (fi) 2009-03-13
NO971951L (no) 1997-04-25
DE69534306T2 (de) 2006-04-27
EP1147766A2 (en) 2001-10-24
CY2211B1 (en) 2002-11-08
GB2308546A (en) 1997-07-02
FI119754B (fi) 2009-03-13
NO2004005I1 (no) 2004-09-20
ATE299017T1 (de) 2005-07-15
CZ289773B6 (cs) 2002-04-17
KR100434682B1 (ko) 2004-08-18
DE69525957T2 (de) 2002-11-14
FI20071025L (fi) 2007-12-28
NO316963B1 (no) 2004-07-12
CN1162259A (zh) 1997-10-15
EP1147766B1 (en) 2005-07-06
SK284591B6 (sk) 2005-07-01
HK1053611A1 (en) 2003-10-31
NO971951D0 (no) 1997-04-25
NO2004005I2 (no) 2007-06-11
HU223840B1 (hu) 2005-02-28
JPH10508588A (ja) 1998-08-25
WO1996013249A1 (en) 1996-05-09
KR970706796A (ko) 1997-12-01

Similar Documents

Publication Publication Date Title
CN1089233C (zh) 药物组合物
CN1149979C (zh) 药物组合物
CN1104256C (zh) 含环孢菌素的软胶囊组合物
CN1195495C (zh) 含有环孢菌素或大环内酯的乳液预浓缩物
CN1178656C (zh) 药物组合物
CN1309414C (zh) 用于给予环孢菌素的亲水二元体系
CN1176826A (zh) 含有环孢菌素的局部用药物组合物
CN1274294C (zh) 环孢菌素类似物微乳液预浓缩物
CN1767856A (zh) 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
CN1208047C (zh) 亲脂性化合物的自体乳化剂
CN1627959A (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
CN1161117C (zh) 药物组合物
CN1183901C (zh) 胶凝药物组合物
CN1933856A (zh) 含有伊维菌素的乳膏－凝胶
CN1251045A (zh) 用于抗细胞增生剂的凝胶释药赋形剂
CN1671367A (zh) 含水2,6－二异丙基苯酚药物组合物
CN1431896A (zh) 含有高脂溶性药物的油性组合物
CN1610550A (zh) 包括免疫反应改性剂的药物制剂
CN1635911A (zh) 胆固醇酯转运蛋白抑制剂的自乳化制剂
CN1076972C (zh) 经皮肤给药的基剂组合物及其药剂组合物
CN1210463A (zh) 透明双氯芬酸钠的水溶液以及它的药物组合物
CN101056619A (zh) 包含喜树碱衍生物的药物组合物
CN1494920A (zh) 含有环孢菌素的软胶囊制剂
CN1239887A (zh) 含n－磺酰基二氢吲哚衍生物的药物组合物
CN1176659C (zh) 具有改进的血管收缩活性的氟替卡松洗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term

Granted publication date: 20020821

EXPY Termination of patent right or utility model